Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TANDEM DIABETES CARE INC

Get SEC filing alerts via email and in your feed for TANDEM DIABETES CARE INC

TNDM

TANDEM DIABETES CARE INC

About TANDEM DIABETES CARE INC

Tandem Diabetes Care designs and manufactures advanced insulin delivery systems, including insulin pumps with Control-IQ technology, for people with insulin-dependent diabetes. Its products serve primarily type 1 and type 2 diabetes patients worldwide, offering automated insulin management, connectivity, and data insights. The company’s business model focuses on innovation, regulatory compliance, and global distribution through direct and partner channels.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TANDEM DIABETES CARE INC

1
1
TANDEM DIABETES CARE INC Tandem Diabetes Care Reports 5.5% Sales Increase to $247.2 Million in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
TANDEM DIABETES CARE INC Tandem Diabetes Care Reports $1.015 Billion Revenue with Increased Losses in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
TANDEM DIABETES CARE INC Tandem Diabetes Care Reports Q3 2025 Revenue of $249.3 Million, Net Loss of $21.2 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TANDEM DIABETES CARE INC Tandem Diabetes Care Reports 8.1% Sales Growth and $52.4 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TANDEM DIABETES CARE INC Tandem Diabetes Care Reports 22.3% Revenue Growth to $234.4 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TANDEM DIABETES CARE INC Tandem Diabetes Care Reports 25.7% Revenue Growth to $940.2 Million for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
TANDEM DIABETES CARE INC Tandem Diabetes Care Reports 31% Revenue Growth, Narrowing Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments